Celsion To Proceed With Phase II Pivotal Breast Cancer Trial After Receiving Supportive FDA Response

Celsion Corporation (AMEX: CLN) announced that it had received a supportive written response from the FDA in relation to its proposed registrational study for use of ThermoDox in patients with recurrent breast cancer at the chest wall. With these FDA responses, Celsion now believes it has established a Phase II protocol which has defined acceptable endpoints in a defined patient population that has an unmet medical need.

More: continued here

Filed under: Breast Cancer on January 17th, 2008